CURRICULUM VITAE

Sana Louise Johnson-Quijada

MD

E-mail: Sana@vikingcr.com

Primary Investigator/Sub-Investigator

Viking Clinical Research, Ltd.

29645 Rancho California Road, Suite 133
Temecula, California 92591
Office: (800) 670-4960
Fax: (800) 670-4969

Associated Sites:

Temecula Valley Psychiatric Medical Group
25405 Hancock Avenue, Suite 108
Murrieta, California 92562

Licenses and Certificates:

California Medical License	A70270 2001
DEA/Narcotics License	BJ6667755
Board Certified in Psychiatry	2007
Massachusetts Board of Registration in Medicine	1999

Research Experience:

GlaxoSmithKline: A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (xxxmg-xxxmg once daily) in Elderly Subjects with Major Depressive Disorder. 2004-2005.

GlaxoSmithKline: A Twelve-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-Release (WELLBUTRIN™SL, xxx-xxxmg/day) and Extended-Release Venlafaxine (EFFEXOR XR, xx-xxxmg/day) in Subjects with Major Depressive Disorder. 2004-2005.

Pfizer Inc: A Phase 3, Randomized, 6-Month, Double-Blind Trial in Subjects with Bipolar I Disorder to Evaluate the Continued Safety and Maintenance of Effect of xxx plus a Mood Stabilizer (vs Placebo plus a Mood Stabilizer) Following a Minimum of 4 Months of Response to Open-Label Treatment with Both Agents. 2006-2008.

7/22/15

7/15/2015

Sanofi Aventis: An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study with XXX as Positive Control, Evaluating the Efficacy, Safety, Tolerability of a Fixed Dose of XX in Outpatients with MDD. 2006-2007.

Novartis: An 8-Week, Randomized, Fixed-Dose, Placebo-Controlled, Parallel-Group, Multi-Center Study of the Efficacy, Safety and Tolerability of XXX and XX mg in the Treatment of Major Depressive Disorder (MDD). 2006-2008.

GlaxoSmithKline: A 12 Week Flexible Dose Study of XXX, Placebo and Active Control in the Treatment of Social Anxiety Disorder (SocAD). 2006-2007.

Sanofi-Aventis: A Multi-Center, Double-Blind, Parallel Group, Fixed Dose, 4-Arm, Placebo and XXX Controlled 8-Week Efficacy Study of 2 Oral Doses of XXX in Adult Outpatients with Major Depressive Disorder. 2007-2008.

Novartis: An 8 week, Randomized, Double-Blind, Fixed-Dosage, Placebo-Controlled Parallel Group, Multi-Center Study of the Safety, Efficacy, and Tolerability of XXX 25mg and 50mg in the Treatment of Major Depressive Disorder Followed by a 52 Week, Open-Label Extension 2007-2008

Pfizer: A Sixteen-Week, Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Switching From Quetiapine to Ziprasidone in Subjects Diagnosed with Schizophrenia or Schizoaffective Disorder 2008

Pfizer: A Phase III, Randomized, Double-Blind-Parallel Group, 10 Week Placebo Controlled Fixed Dose Study of XXXX and Paroxetine Evaluating the Efficacy and Safety of XXXX for the Treatment of Generalized Anxiety Disorder. 2008-2009

Pfizer: A Phase 3, 52-Week, Open-Label Safety Study of XXX in Subjects With Generalized Anxiety Disorder 2008-2009

Wyeth: An Open-Label Study to Evaluate the Prevalence of Phenotypic Poor Metabolizers at CYP2D6 Among Venlafaxine-Treated Outpatients with Depression 2009

Cephalon: A Double Blind, Placebo Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of ********** in Adults with Major Depression Associated with Bipolar I Disorder 2010-2011

Novartis: An 8-Week, Randomized, Double Blind. Placebo Controlled, Parallel Group, Multi-Center Study of the Efficacy and Safety of ********* 0.5mg and 1mg Sublingual Tablets Administered Once Daily in Patients with Major Depressive Disorder (MDD) 2010-2011

Novartis: A 12-week, Randomized, Multi-center, Open-Label, *********, (12-24mg/day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole 2010-2012

Pfizer: A Phase IV, Multicenter, Randomized, 8-week, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy Of 2 Fixed Doses (50 AND 100 MG/DAY) Of ********** In Adult Outpatients with Major Depressive Disorder. 2011-2012

Otsuka: A **P**hase 3, Multicenter, Rand**o**mized, Double-blind, **P**lacebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of ******** as **A**djunctive Ther**a**py **i**n the Treatment of Adults with Major Depr**e**ssive Disorder 2011-

Otsuka: A Long-term, Phase 3, Multicenter, **O**pen-label **T**rial to Evaluate the Safety and Toler**a**bility of **O**ral ******* as Adju**n**ctive Therapy in Adults with Major Depressive Disorder, 2011-

Forest: A Double-blind, Placebo-Controlled Evaluation of the Safety and Efficacy of ******* in Patients With Bipolar Depression 2011-

Forest: A Double-Blind, Placebo- and Active-Controlled, Fixed-Dose Study of ******** in Patients with Major Depressive Disorder 2011-

Eli Lilly: A Randomized Placebo-Controlled, Double-Blind Study of ******** Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment 2012-

Forest: A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ******* AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER 2012-

Forest: A PHASE 3, LONG-TERM, OPEN-LABEL STUDY OF SAFETY AND TOLERABILITY OF ******* AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER. 2012-

Forest: A Double-Blind, Placebo-Controlled, Flexible-Dose Study of ******** in Patients with Generalized Anxiety Disorder. 2012-

Otsuka: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of xxxxxxxxxxxxx as Maintenance Treatment in Patients with Bipolar I Disorder 2013-

Lundbeck: Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of xxxxxxxx as adjunctive treatment in patients with major depressive disorder with an inadequate response to antidepressant treatment 2014-

Otsuka: A Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction with xxxxxxxx as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy 2014

Alkermes: A Phase 3 Efficacy and Safety Study of xxxxxxx for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study) 2014-

Alkermes: A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of xxxxxxx for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study) 2014-

Edgemont: A Randomized Double-Blind, Placebo Controlled, Flexible Dose, Parallel Group Study of Extended-Release xxxxxxxxxx for the Treatment of Generalized Anxiety Disorder (GAD) 2015-

Professional Experience:

Investigator, Viking Clinical Research Temecula, CA	2004-Present
Private Practice, Temecula Valley Psychiatric Medical Group Temecula, CA	2004-Present
Service Director, Staff Psychiatrist Canyon Ridge Hospital Chino, CA	2002-2005
Staff Psychiatrist California Rehabilitation Center Norco, CA	2002-2003
Staff Psychiatrist Faulkner Hospital Boston, MA	2002-2002
Staff Psychiatrist Mt. Auburn Hospital Cambridge, MA	2002-2002
Staff Psychiatrist Newton-Wellesley Newton, MA	2002-2002
Staff Psychiatrist Cambridge Psychiatric Services Cambridge, MA	2002-2002

Education:

Bachelor of Science Degree Major: Biology La Sierra, Riverside, CA	1994
MD Degree Loma Linda University, Loma Linda, CA	1998
Internship and Residency Loma Linda University, Loma Linda, CA	2001
Chief Resident in Psychiatry Harvard South Shore, Brockton, MA	2002

Presentation Experience:

Loma Linda University Medical Center:	2003 Rotary Club, Corona "Sleep Disorders"
	2001 Teaching Seminar, Lake Arrowhead "Depression"
Harvard Medical School:	2002 Instructor, Harvard Medical School Intro to Clinical Medicine
	Faculty/Staff Teaching Conference West Roxbury VA Hospital "Somatoform Disorders"
	Physical Medicine & Rehabilitation Conference West Roxbury VA Hospital "Character Disorders, Somatoform Disorders"

Hospital Staff Appointments:

Harvard South Shore House Staff Psychiatrist Brockton, MA	2001-2002
Kaiser Permanente Staff Psychiatrist Fontana, CA	2001-2001
Inland AIDS Clinic Staff Psychiatrist San Bernardino, CA	2001-2001
Temecula Psychiatric Services Staff Psychiatrist Temecula, CA	2000-2001
Loma Linda University House-Staff Psychiatrist Loma Linda, CA	1998-2001

Ryan

From: Perkins, Michael <Michael.Perkins@INCResearch.com>
Sent: Wednesday, July 15, 2015 3:21 PM
Cc: Andreeva, Albena; Bailey, Ryan; Christian, Bridget; Harrison, Mark; Kujanson, Roxanne; Lease, Shery; Lourentzos, Anne; Olieberg, Harold; Singh, Gina; vonRentzell, Elizabeth; Uphoff, Julie; Arnold, Julie; Gagne, Jean-Francois; Konovalova, Elena; Schlosz, Lisa; SM_1003456; Doncheva, Hristina; Andreeva, Albena; Massink, Jurgen
Subject: ALK5461 FORWARD-3 Summertime Sprint Update - Week 6

Dear FORWARD-3 Investigators and Site Staff

After six weeks of the Summertime Sprint competition, sites have screened a total of 120 subjects. Sites screened 26 subjects during week 6.
Our study wide goal is to reach 1410 subjects screened by the end of August! As of today we've screened a total of 1294 subjects, requiring us to screen an additional 116 subjects over the rest of the summer.

Week 6 highlights:
Drs. Franklin and Joyce tied for most screenings during week 6 with 4 screenings!
Drs. Habib, Kline and Saini screened their first subject of the competition!
Dr. Joyce's site bumped their Summertime Sprint screening total 15!

Another great week! Thanks to all sites for the hard work!

If any sites require replenishments of Forward site/subject materials or want to discuss advertising, please contact me.

Summertime Sprint screening contributions by site for the week of **7/6/15 – 7/10/15** are as follows:



Cumulative Summertime Sprint site totals are as follows (6/1/15 – 7/10/15):

Cumulative Summertime Sprint Totals



Cumulative Summertime Sprint Totals Cont.



Sincerely

Michael Perkins | Project Specialist | CNS
4801 Southwest Parkway, Bldg 2, Suite 250
Austin, TX 78735 | USA
Office: (512) 306-4287
VoIP: (512) 703-4287
Michael.Perkins@INCResearch.com
www.INCResearch.com | **INC Research®**

Notice: